Skip to content
sellWeak10b5-1 plan

Jack Bendheim sold $1.2M of PAHC

President and CEO at PHIBRO ANIMAL HEALTH CORP. 22,880 shares at an average of $52.40, traded Mar 17, 2026, filed Mar 19, 2026.

Warning score
35
Value
$1.2M
22,880 shares
Holdings after
73,320
-24% from before
From 52-week low
+222%
low $16.19, close $52.13
From 52-week high
-4%
high $54.17, as of Mar 17, 2026

Score components

  • Role
    CEO
    +25
  • Trade size
    $1.2M at market
    +25
  • Share of holdings sold
    Sold 24% of holdings
    +5
  • Cluster
    No other insider selling within 14 days
    0
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +9.0%, 3m -38.9%, 6m -33.8%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

PAHCOct 12, 2026 · close 37.43
Since filing Mar 19, 2026: -28.0%SPY +18.8% · excess -46.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-26-032252, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 17, 2026SOpen-market sale
Class A Common Stockindirect: See10b5-1
-5,280$51.66$273k90,920Mar 19, 2026
Mar 18, 2026SOpen-market sale
Class A Common Stockindirect: See10b5-1
-4,311$51.80$223k86,609Mar 19, 2026
Mar 18, 2026SOpen-market sale
Class A Common Stockindirect: See10b5-1
-3,598$53.03$191k83,011Mar 19, 2026
Mar 18, 2026SOpen-market sale
Class A Common Stockindirect: See10b5-1
-2,651$53.64$142k80,360Mar 19, 2026
Mar 19, 2026SOpen-market sale
Class A Common Stockindirect: See10b5-1
-1,939$51.78$100k78,421Mar 19, 2026
Mar 19, 2026SOpen-market sale
Class A Common Stockindirect: See10b5-1
-4,977$52.79$263k73,444Mar 19, 2026
Mar 19, 2026SOpen-market sale
Class A Common Stockindirect: See10b5-1
-124$53.24$6,60273,320Mar 19, 2026

Related signals

Other insiders at PHIBRO ANIMAL HEALTH CORP and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
43Moderate
PAHCbuy
PHIBRO ANIMAL HEALTH CORP
E Thomas Corcoran
director
$318k
10,000 shares
+32%
35Weak
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.0M
18,608 shares
-25%
35Weak
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.1M
21,120 shares
-22%
35Weak
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.2M
21,120 shares
-18%
50Moderate
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.2M
21,120 shares
-55%
37Weak
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$757k
14,080 shares
-27%
40Moderate
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.2M
21,120 shares
-29%
18Weak
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$258k
5,280 shares
-5%
50Moderate
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$1.1M
21,120 shares
-93%
36Weak
PAHCsell10b5-1
PHIBRO ANIMAL HEALTH CORP
Jack Bendheim
President and CEO
$716k
14,080 shares
-38%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Jack Bendheim sold $1.2M of PAHC | InsiderTell